Nearly 40% of adults in the United States are obese: a number that is expected to continuously rise. Because of the risks associated with obesity, including cardiovascular disease and type 2 diabetes, education regarding weight loss pharmacotherapy is crucial to assist in mitigating its impacts. Because obesity is recognized as a disease, it is necessary to treat it as a chronic condition, rather than a result of unhealthy lifestyle choices. Nevertheless, few clinicians regard obesity as a disease, and many remain reluctant to include pharmacologic therapy as part of their patients’ weight-loss plans. Consequently, many clinicians remain unaware of recent advancements and developments in obesity pharmacotherapy. This workshop will review the need for obesity pharmacotherapy and the latest evidence in the field, in addition to current challenges: allowing participants to become more familiar with the safety and efficacy data for these agents. Attendees will be able to create multifactorial weight-management plans that utilize the full armamentarium of evidence-based weight-loss strategies.